 NEW YORK, June 1, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been included in the Defiance Next Gen Altered Experience ETF, the first U.S. listed Exchange Traded Fund ETF focused on psychedelics which began trading on Friday, May 28 th on the New York Stock Exchange under the symbol PSY. Seelos inclusion is based on its lead program SLS-002 intranasal racemic ketamine, which recently released positive top-line data from Part 1, the open-label cohort, of its potentially registrational Proof-of-Concept study for Acute Suicidal Ideation and Behavior ASIB in patients with Major Depressive Disorder MDD. 